A NOVEL ULTRAFAST LASER TECHNIQUE FOR PATHOGEN INACTIVATION
用于灭活病原体的新型超快激光技术
基本信息
- 批准号:8398796
- 负责人:
- 金额:$ 2.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAreaBacteriaBiological ProductsBloodBlood Coagulation FactorBlood PlateletsBlood TransfusionBlood VolumeBlood-Borne PathogensCapsidCapsid ProteinsChemical AgentsChemicalsClinicalCoagulation ProcessDetergentsDevelopmentDiseaseDonor SelectionElectron MicroscopyEmergency SituationEnsureErythrocytesExcisionFutureGoalsHIVHeatingHepatitis C virusHumanImmunocompromised HostImmunologic TestsInfectionLasersMass Spectrum AnalysisMeasuresMedicalMedical DeviceMedicineMethodsMilitary PersonnelModelingMolecularMusNucleic AcidsOne-Step dentin bonding systemPharmacologic SubstancePlasmaPlasma ProteinsPolymerase Chain ReactionProcessRNARelative (related person)ResistanceResourcesRiskSafetySamplingScreening procedureSolutionsSolventsSterilizationStructureSurgical InstrumentsSurgical woundSystemTechniquesTechnologyTestingTherapeuticTransfusionTranslationsUltraviolet RaysUnited StatesVascular blood supplyViralVirusVirus InactivationVisible RadiationWest Nile virusWhole Bloodbaseblood productcombatcostionizationirradiationkillingsmouse modelnovelnovel strategiespathogenultraviolet
项目摘要
DESCRIPTION (provided by applicant): Pathogen reduction (PR) represents the ideal preemptive measure to ensure the safety of the blood supply. However, currently available PR technologies have concerns of clinical side effects, limiting their use in the United States. The ideal PR technology should be able to effectively kill a wide variety of pathogens without introducing chemical or biological agents, while retaining the function of the blood products. In this regard, ultrafast lasers represent a promising new chemical-free PR technology. The objective of the proposed studies is to establish an ultrafast laser PR technology for treatment of
human plasma, and to determine the physical and molecular mechanisms by which ultrafast lasers kill pathogens. The long-term goal of the proposed studies is to develop an ultrafast laser PR system applicable to plasma, platelets and red blood cells to provide safe transfusion worldwide. The specific aims of the project are: (1) To demonstrate ultrafast laser inactivation of
West Nile virus (WNV), a model transfusion-transmitted pathogen; (2) To determine the physical and molecular basis of ultrafast laser-induced inactivation of pathogens; and (3) To determine efficacy of WNV inactivation in a mouse model of plasma transfusion. At the completion of the project, we expect to have made significant progress in the development of a new ultrafast laser technology for PR of plasma, amenable to use in a clinical setting. We anticipate translation of this technology soon to PR of platelets, RBCs, and whole blood in future studies. This technology will also be especially beneficial in military use, such as for emergency transfusions in the field, and low resource areas worldwide where screening and testing are not well established. To our knowledge, this is the first use of ultrafast lasers in the field of transfusio medicine and represents a new medical application for lasers. Continued exploration of this laser PR technology is expected to generate additional applications including sterilization of pharmaceuticals, medical devices, surgical wounds, and surgical instruments, and combating bioterror threats.
PUBLIC HEALTH RELEVANCE: Known and emerging pathogens will continue to be a threat to the blood supply until an effective pathogen reduction technology is in place. In the proposed studies, we will develop a new ultrafast laser pathogen inactivation technology with the goal of eliminating the risk of transfusion-transmitted diseases worldwide.
描述(由申请方提供):病原体减少(PR)是确保血液供应安全的理想预防措施。然而,目前可用的PR技术存在临床副作用的问题,限制了它们在美国的使用。理想的PR技术应该能够在不引入化学或生物制剂的情况下有效地杀死各种病原体,同时保留血液制品的功能。在这方面,超快激光代表了一种有前途的新的无化学PR技术。拟议研究的目的是建立一种超快激光PR技术用于治疗
人类血浆,并确定超快激光杀死病原体的物理和分子机制。拟议研究的长期目标是开发适用于血浆、血小板和红细胞的超快激光PR系统,以在全球范围内提供安全输血。本项目的具体目标是:(1)证明超快激光灭活
西尼罗河病毒(WNV),一种输血传播的病原体模型;(2)确定超快激光诱导病原体灭活的物理和分子基础;(3)确定WNV灭活在小鼠血浆输注模型中的效力。在该项目完成后,我们预计将在开发用于血浆PR的新超快激光技术方面取得重大进展,该技术适用于临床环境。我们预计在未来的研究中,这项技术很快就会转化为血小板、红细胞和全血的PR。这项技术在军事用途上也将特别有益,例如在实地紧急输血,以及在筛查和测试尚未完善的世界各地资源匮乏的地区。据我们所知,这是超快激光在输血医学领域的首次应用,代表了激光的一种新的医学应用。对这种激光PR技术的持续探索有望产生更多的应用,包括药品、医疗器械、手术伤口和手术器械的消毒,以及应对生物恐怖威胁。
公共卫生相关性:已知和新出现的病原体将继续对血液供应构成威胁,直到有效的病原体减少技术到位。在拟议的研究中,我们将开发一种新的超快激光病原体灭活技术,目标是消除全球输血传播疾病的风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shaw-Wei David Tsen其他文献
Shaw-Wei David Tsen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shaw-Wei David Tsen', 18)}}的其他基金
A NOVEL ULTRAFAST LASER TECHNIQUE FOR PATHOGEN INACTIVATION
用于灭活病原体的新型超快激光技术
- 批准号:
8699831 - 财政年份:2012
- 资助金额:
$ 2.84万 - 项目类别:
A NOVEL ULTRAFAST LASER TECHNIQUE FOR PATHOGEN INACTIVATION
用于灭活病原体的新型超快激光技术
- 批准号:
8527527 - 财政年份:2012
- 资助金额:
$ 2.84万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 2.84万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 2.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 2.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 2.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 2.84万 - 项目类别:
Discovery Grants Program - Individual